Found 11 clinical trials
Dupilumab_Metastatic NSCLC
. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents
- 0 views
- 16 Oct, 2021
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1
- 1 views
- 19 Jun, 2021
- 5 locations
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
- 20 views
- 20 Oct, 2021
- 19 locations
Atezolizumab and Cobimetinib in Treating Patients With Metastatic Recurrent or Refractory Non-small Cell Lung Cancer
This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the …
- 54 views
- 24 Oct, 2021
- 8 locations
Ph I/II Trial of Systemic VSV-IFN -NIS and Pembrolizumab in Refractory NSCLC and NEC
expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion
- 0 views
- 20 Oct, 2021
- 1 location
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
- 0 views
- 03 Sep, 2021
- 1 location
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
- 1 views
- 25 Jan, 2021
- 3 locations
Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).
advanced, refractory NSCLC and to detect a potential disease control signal when employed in combination with low dose chemotherapy (ie, paclitaxel), immunotherapy (ie, atezolizumab) in patients who
- 0 views
- 26 Jan, 2021
- 3 locations
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel
- 0 views
- 24 Oct, 2021
- 6 locations
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer nave to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who …
- 29 views
- 27 Sep, 2021
- 7 locations
- 1
- 2